Lucentis gets another FDA approval.

The FDA announced the approval of Lucentis to treat myopic choroidal neovascularization (mCNV) making this the fifth FDA approved indication for Lucentis.  This approval is based on the results of the Phase 3 RADIANCE study, which demonstrated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy. (via)
To recap, Lucentis is now FDA approved for

  • wet AMD
  • macular edema after retinal vein occlusion
  • diabetic macular edema
  • diabetic retinopathy
  • myopic choroidal neovascularization
Jaclyn Garlich
Dr. Garlich graduated from the New England College of Optometry in 2010 and completed a residency in primary care and ocular disease at the St. Louis VA. In 2013, she developed an optometry clinical reference mobile app available in the iTunes store. In 2016, she founded 20/20 Glance, a weekly optometry newsletter that gives a rundown on clinically relevant optometry news in an easy to digest format.

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts